NYSE - Delayed Quote USD

Enzo Biochem, Inc. (ENZ)

1.0700 +0.0100 (+0.94%)
At close: 4:00 PM EDT
1.0700 0.00 (0.00%)
After hours: 4:01 PM EDT
Loading Chart for ENZ
DELL
  • Previous Close 1.0600
  • Open 1.0400
  • Bid 1.0400 x 1100
  • Ask 1.0500 x 900
  • Day's Range 1.0400 - 1.0800
  • 52 Week Range 1.0400 - 2.7400
  • Volume 74,023
  • Avg. Volume 108,491
  • Market Cap (intraday) 54.812M
  • Beta (5Y Monthly) 0.71
  • PE Ratio (TTM) --
  • EPS (TTM) -0.4700
  • Earnings Date Jun 12, 2024 - Jun 17, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

www.enzo.com

179

Full Time Employees

July 31

Fiscal Year Ends

Recent News: ENZ

Performance Overview: ENZ

Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ENZ
23.02%
S&P 500
5.84%

1-Year Return

ENZ
57.87%
S&P 500
22.03%

3-Year Return

ENZ
67.18%
S&P 500
20.77%

5-Year Return

ENZ
70.44%
S&P 500
72.46%

Compare To: ENZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ENZ

Valuation Measures

Annual
As of 4/24/2024
  • Market Cap

    54.30M

  • Enterprise Value

    1.24M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.61

  • Price/Book (mrq)

    0.77

  • Enterprise Value/Revenue

    0.04

  • Enterprise Value/EBITDA

    -0.08

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    99.28%

  • Return on Assets (ttm)

    -16.53%

  • Return on Equity (ttm)

    -45.01%

  • Revenue (ttm)

    32.8M

  • Net Income Avi to Common (ttm)

    -23.32M

  • Diluted EPS (ttm)

    -0.4700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    60.24M

  • Total Debt/Equity (mrq)

    10.15%

  • Levered Free Cash Flow (ttm)

    -4.44M

Research Analysis: ENZ

Analyst Price Targets

 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Company Insights: ENZ

Fair Value

1.0700 Current
 

Dividend Score

0 Low
ENZ
Sector Avg.
100 High
 

Hiring Score

0 Low
ENZ
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
ENZ
Sector Avg.
100 High
 

People Also Watch